Nebivaolol Effect in Patients with Chronic Obstructive Disease of the Lungs

Abstract

ABSTRACT. Introduction: Chronic obstructive disease of the lungs (CODL) is one of the leading cases of morbidity and mortality all over the world. It is one of the causes which may form the basis of sudden death, it serves as disturbance of cardiac contractions rhythm. Aim of the research is to evaluate the effect of adrenoreceptor -nebivaolol by selective blocker β1 on pulmonary hypertension degree in patients with chronic obstructive disease of the lungs. Material and methods: 60 patients with chronic obstructive disease of the lungs of III-IV stage in exacerbation phase were enrolled in the study. The patients were subdivided into 2 groups: group A for comparison (n-25) and group B for study (n=35). The patients of both groups received standard therapy, directed to elimination of inflammatory process and improvement of bronchial permeability: antibiotics, broncholytics, mucolytics. The patients of group B were treated with nebivaolol in the dosage 10 mg 24 hours (5 mg dose 2 times 24 hours) for 14 days. Results: In absence of negative effect on hemodynamic indexes, electrophysiological parameters and sporometric data reveal changes in the rate of cardiac contractions to adequate values and significant increase of tolerance to physical exertion in 2 weeks after taking nebivaolol. Decrease of heart rate correlates with decrease of pulmonary hypertension. Conclusion: Taking into account the received findings nebivaolol can be recommended for treatment of patients with chronic obstructive disease of the lungs and pulmonary hypertension.